In a randomized, double-blind, vehicle controlled, Phase 2 clinical trial of 122 patients, PR022 showed no difference from vehicle in the primary endpoint of percent change in Eczema Area Severity Index (EASI) versus baseline.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”